The experts found that there were no differences between the two groups with regards to cognitive decline. In addition they found no overall distinctions between the two groupings in the switch in the amount of neuropsychiatric symptoms. Patients with severe neuropsychiatric problems at the outset of the trial may experienced some benefit from continued neuroleptic therapy, but this difference was not significant statistically. Related StoriesHealth Education England launches Dementia Core Skills Education and Training FrameworkLewy Body Composite Risk Rating detects LBD and Parkinson's disease dementia in 3 minutesMayo Clinic's Florida campus awarded NIH grant to identify vascular risk elements in ageing and dementiaAlmost all older dementia sufferers will have some neuropsychiatric symptoms.Aetna Whole Health programs unite Aetna’s network of contracted suppliers and small-group programs with doctors, outpatient and hospitals specialty centers from Carilion Clinic and LewisGale Regional Health System. The plans are costed to reflect the cost and quality benefits of the Aetna-Carilion collaboration. Members can reap the benefits of a minimal co-pay differential by using ‘designated network providers’ who have been recognized or are along the way of being acknowledged by the National Committee for Quality Assurance for meeting stringent effectiveness and quality measures.